ai-facial-speech-patterns-pd-nct07392411

Migration, Crosslink

📖

ai-facial-speech-patterns-pd-nct07392411

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-ai-facial-speech-pa

📖 Wiki Page

clinical_trial3086 wordssynced 2026-04-02

AI-Based Facial/Speech Patterns in Parkinson's Disease (NCT07392411)

Overview

flowchart TD clinical_trials_ai_facial_spee["ai-facial-speech-patterns-pd-nct07392411"] style clinical_trials_ai_facial_spee fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_ai_f_0["Study Details"] clinical_trials_ai_facial_spee -->|"includes"| clinical_trials_ai_f_0 style clinical_trials_ai_f_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_ai_f_1["Scientific Background"] clinical_trials_ai_facial_spee -->|"includes"| clinical_trials_ai_f_1 style clinical_trials_ai_f_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_ai_f_2["Facial Expression Impairment in Parkinsons Dise"] clinical_trials_ai_facial_spee -->|"includes"| clinical_trials_ai_f_2 style clinical_trials_ai_f_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_ai_f_3["Speech Impairment in Parkinsons Disease"] clinical_trials_ai_facial_spee -->|"includes"| clinical_trials_ai_f_3 style clinical_trials_ai_f_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_ai_f_4["Objectives"] clinical_trials_ai_facial_spee -->|"includes"| clinical_trials_ai_f_4 style clinical_trials_ai_f_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_ai_f_5["Primary Objectives"] clinical_trials_ai_facial_spee -->|"includes"| clinical_trials_ai_f_5 style clinical_trials_ai_f_5 fill:#81c784,stroke:#333,color:#000

...

AI-Based Facial/Speech Patterns in Parkinson's Disease (NCT07392411)

Overview

Mermaid diagram (expand to render)

This observational study develops and validates AI-powered analysis of facial expressions and speech patterns as digital biomarkers for [Parkinson's disease](/diseases/parkinsons-disease), [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy), and related neurodegenerative disorders. The study leverages computer vision and speech signal processing to identify objective, quantifiable measures of disease severity and progression["@Ma_2020"].

Study Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07392411 |
| Status | Recruiting |
| Study Type | Observational |
| Conditions | Parkinson's Disease, PSP |
| Sites | China |

Scientific Background

Facial Expression Impairment in Parkinson's Disease

Hypomimia (reduced facial expression) is a cardinal feature of Parkinson's disease, resulting from dopaminergic degeneration in the substantia nigra affecting facial motor control[@Scarpetta_2023]. This "masked face" appearance manifests as:

Reduced spontaneous blinking
Decreased emotional expressivity
Monotonous speech with reduced intonation
Delayed facial movement initiation

Studies have shown that facial expression deficits correlate with disease duration, motor severity, and cognitive status[@Moreau_2008]. Importantly, these impairments can be detected quantitatively using computer vision algorithms.

Speech Impairment in Parkinson's Disease

Speech dysfunction (hypokinetic dysarthria) affects up to 90% of Parkinson's disease patients[@Bologna_2016]. Characteristic features include:

Reduced vocal intensity: Soft, monotone speech
Monopitch: Limited pitch variation
Imprecise articulation: Fuzzy consonant production
Harsh voice quality: Breathiness and roughness

Speech analysis provides a non-invasive, cost-effective method for disease monitoring[@Arora_2018]. Quantitative speech measures can detect subclinical changes and track progression over time.

Objectives

Primary Objectives

Develop Automated Facial Expression Analysis

Computer vision algorithms for facial landmark detection
Quantification of micro-expression frequency
Correlation with clinical severity scales[@Ma_2020]

Validate Speech Acoustic Features as Biomarkers

Acoustic analysis of speech samples
Voice quality measures (jitter, shimmer, harmonic-to-noise ratio)
Correlation with MDS-UPDRS scores[@Rusz_2021]

Correlate Digital Markers with Clinical Severity

Link AI-derived metrics to standard clinical assessments
Validate against neurologist ratings
Establish sensitivity to change[@Oung_2022]

Test Utility for Remote Monitoring

Smartphone-based data collection
Telemedicine applications
Continuous home monitoring potential

Secondary Objectives

Compare PD versus PSP digital phenotypes
Identify early detection markers
Develop machine learning classifiers for differential diagnosis

Technology and Methods

Computer Vision Pipeline

| Component | Description |
|-----------|--------------|
| Face Detection | Deep learning-based facial landmark localization |
| Expression Analysis | Facial Action Coding System (FACS) analysis |
| Blink Rate Detection | Automated measurement of spontaneous blinking |
| Micro-expression Capture | High-frame-rate analysis of subtle movements |

Speech Processing

| Feature | Clinical Relevance |
|---------|-------------------|
| Fundamental frequency (F0) | Voice pitch stability[@Tsanas_2012] |
| Formant frequencies | Articulatory precision |
| Jitter | Cycle-to-cycle frequency variation |
| Shimmer | Cycle-to-cycle amplitude variation |
| Harmonic-to-noise ratio | Voice quality |

Machine Learning Classifiers

The study employs various machine learning approaches[@Hanczar_2023]:

Support Vector Machines (SVM): Classification of disease states
Random Forests: Feature importance for biomarker selection
Deep Neural Networks: End-to-end feature extraction
Recurrent Neural Networks (RNN): Temporal pattern analysis

Clinical Assessments

Motor Evaluation

MDS-UPDRS Part III: Motor examination (OFF and ON states)
Hoehn & Yahr Staging: Disease severity scale
Timed Up and Go Test: Functional mobility

Facial Expression Rating

Facial Expression Rating Scale: Standardized emotion expression assessment
Blink Rate Measurement: Automated and manual counting
Facial Motion Analysis: Quantitative movement metrics

Speech Assessment

Diadochokinetic Rate: Rapid syllable repetition (/pa-ta-ka/)
Sustained Vowel Production: /a/ for 10 seconds
Reading Passage: Standardized speech sample
Conversation Sample: Spontaneous speech analysis

Patient-Reported Outcomes

PDQ-39: Parkinson's Disease Questionnaire-39
MDS-UPDRS Part I: Non-motor experiences of daily living
Voice Handicap Index: Perceived speech impairment

Target Populations

Parkinson's Disease

The study is particularly relevant for PD because:

Hypomia is a key clinical feature present in >80% of patients
Speech dysfunction (dysarthria) is nearly universal
Digital markers may detect early changes before motor onset

Progressive Supranuclear Palsy

PSP presents distinct phenotypes that may be detectable through digital analysis:

Richardson Variant: Early postural instability, vertical gaze palsy
PSP-Parkinsonism: Asymmetric onset with poor levodopa response
Pure Akinesia with Gait Freezing: Progressive gait disturbance

The study may help differentiate PSP from PD using speech and facial patterns.

Significance and Applications

Clinical Utility

Digital biomarkers offer several advantages[@Perez_Llorens_2023]:

Objective Quantification: Eliminates subjective rating variability

Frequent Assessment: Enables continuous monitoring beyond clinic visits

Remote Data Collection: Facilitates telemedicine and home monitoring

Early Detection: May identify pre-symptomatic changes

Research Applications

Clinical trial endpoint development
Disease progression modeling
Drug response monitoring
Phenotype characterization

Healthcare Delivery

Triage and screening in primary care
Remote patient monitoring programs
Virtual trial infrastructure

Digital Biomarkers in Neurodegeneration

Comparison of Digital Measures

| Modality | Advantages | Limitations |
|----------|------------|--------------|
| Speech analysis | Non-invasive, remote, low-cost | Environmental noise, accent variation |
| Facial analysis | Objective, quantifiable | Camera quality, lighting conditions |
| Gait analysis | Sensitive to motor impairment | Requires specialized equipment |
| Keyboard/mouse | Ubiquitous, passive | Limited specificity |

Emerging Evidence

Recent studies demonstrate the potential of speech and facial analysis:

Speech measures can differentiate PD from healthy controls with >80% accuracy[@Rusz_2021]
Facial expression analysis correlates with UPDRS motor scores[@Ma_2020]
Machine learning models show promise for differential diagnosis[@Hanczar_2023]
Remote monitoring is feasible and acceptable to patients[@Marsal_Catala_2024]

Eligibility Criteria

Inclusion Criteria

Diagnosis: Confirmed Parkinson's disease or PSP according to established criteria

Age: 18 years or older

Ability to Perform Tasks: Capable of performing facial expression and speech tasks

Consent: Willingness to provide video and audio recordings

Exclusion Criteria

Significant visual impairment affecting facial expression assessment

Severe hearing impairment affecting speech production

Current speech or facial therapy

Previous facial surgery or botulinum toxin injection

Other neurological conditions affecting speech or facial movement

External Links

[ClinicalTrials.gov NCT07392411](https://clinicaltrials.gov/study/NCT07392411)
[Parkinson's Foundation Digital Health](https://www.parkinson.org/)
[MJFF Digital Health Initiative](https://www.michaeljfox.org/)

[Digital Endpoints in Parkinson's Disease
MOTIVE-PSP Initiative
PAROPE Study
AI-Enhanced Levodopa Challenge Test
Remote Monitoring in Neurodegeneration](/diseases/parkinsons-disease)## Scientific Background: Facial and Speech Dysfunction in PD and PSP

Facial Dysfunction: Hypomimia and Masking

Facial hypomimia, also known as "facial masking" or "mask-like facies," is one of the cardinal motor features of Parkinson's disease and is also prominent in PSP. This phenomenon results from the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced facial muscle movement.

Pathophysiology

The facial expression deficiency in parkinsonian syndromes involves:

Basal ganglia dysfunction: The indirect pathway becomes overactive, inhibiting facial motor cortex output

Muscle rigidity: Decreased facial muscle elasticity leads to reduced spontaneous movements

Bradykinesia: Slowness in initiating and executing facial movements

Reduced blink rate: Decreased blink frequency contributes to the "staring" appearance

Clinical Manifestations

Facial hypomimia encompasses:

Reduced facial expressiveness: Decreased spontaneous emotional expression
Mask-like appearance: Fixed, expressionless facies
Reduced eye blinking: Typically less than 5-10 blinks per minute (normal: 15-20)
Micrographia-like facial movements: Small amplitude facial expressions
Impaired emotional decoding: Difficulty recognizing others' emotions

Speech Dysfunction: Hypokinetic Dysarthria

Speech impairment in parkinsonian syndromes results from the same dopaminergic deficiency affecting the motor systems involved in speech production.

Speech Characteristics

The hypokinetic dysarthria in PD and PSP includes:

Reduced loudness (hypophonia): Soft, monotone speech

Monopitch: Limited pitch variation

Monoloudness: Limited volume variation

Reduced stress: Decreased accent on stressed syllables

Imprecise articulation: Blurred consonant production

Rapid rate: Accelerated speech rate with decreased pause time

Breathiness: Inefficient breath support

Neuroanatomical Basis

Speech production involves a distributed network:

Motor cortex: Direct cortical output to speech muscles
Basal ganglia: Rhythm and timing of speech movements
Cerebellum: Coordination and fluency
Brainstem nuclei: Cranial nerve innervation
Laryngeal and respiratory system: Breath support and phonation

In PD and PSP, basal ganglia dysfunction disrupts the temporal coordination of these components, producing the characteristic speech pattern.

Facial-Speech Connection in PSP

In Progressive Supranuclear Palsy, facial and speech dysfunction often coexist with:

Early vertical gaze palsy: Impairs visual communication
Axial rigidity: Affects postural support for speech
Cognitive decline: Reduces communicative intent
Pseudobulbar affect: May cause involuntary emotional expressions

AI-Powered Digital Biomarkers

Computer Vision for Facial Analysis

Technical Approach

The study employs advanced computer vision algorithms:

Facial landmark detection: Identifying key points (eyes, mouth, eyebrows)

Facial action unit (AU) analysis: Quantifying individual muscle movements

Temporal analysis: Tracking changes over time

3D facial reconstruction: Capturing depth information

Emotion classification: Mapping facial patterns to emotional states

Machine Learning Pipeline

Video Input → Face Detection → Landmark Tracking → Feature Extraction → Model Prediction

Key features extracted:

AU intensity: Magnitude of each facial action unit
AU frequency: How often each unit is activated
Temporal dynamics: Timing and sequencing of movements
Micro-expression analysis: Brief, involuntary facial expressions

Clinical Applications

Facial AI analysis provides:

Objective quantification: Replacing subjective clinical ratings
Continuous monitoring: Assessment beyond clinic visits
Early detection: Identifying subtle changes before clinical evident
Treatment response: Quantifying medication or therapy effects
Progression tracking: Longitudinal disease monitoring

Speech Signal Processing

Acoustic Feature Extraction

Speech analysis extracts multiple acoustic features:

Prosodic features: Pitch (F0), intensity, duration

Formant frequencies: Vocal tract resonances (F1, F2, F3)

Jitter and shimmer: Cycle-to-cycle pitch and amplitude variation

Harmonics-to-noise ratio: Voice quality measure

Speech rate: Syllables per second, pause ratio

Machine Learning Classification

Speech-based ML models can:

Differentiate disease states: PD vs. PSP vs. healthy controls
Predict severity: Correlation with MDS-UPDRS scores
Track progression: Monitor longitudinal changes
Detect treatment effects: Levodopa response assessment

Digital Biomarker Validation

The integration of facial and speech analysis allows:

Triangulation: Multiple data streams for robust classification

Complementary information: Different aspects of communication

Error reduction: Cross-validation between modalities

Correlation with Clinical Measures

Digital biomarkers are validated against:

MDS-UPDRS Part III: Motor examination scores
Facial Expression Rating Scale: Clinical facial assessment
Hoehn and Yahr staging: Disease severity staging
Quality of life measures: PDQ-39, voice handicap index

Clinical Trial Design

Study Population

Target Conditions

Parkinson's Disease:

Idiopathic PD per UK Brain Bank criteria
Hoehn and Yahr stage 1-3
Stable medication for 4 weeks

Progressive Supranuclear Palsy:

NINDS-SPSP criteria for probable or definite PSP
MRI consistent with PSP diagnosis

Sample Size Considerations

Power analysis based on:

Expected effect size for facial/speech differences
Anticipated drop-out rate
Required precision for biomarker validation

Assessment Protocol

Video Recording Session

Standardized conditions for facial recording:

Lighting: Controlled, diffuse lighting
Distance: 50-70 cm from camera
Duration: 3-5 minutes of various facial tasks
Tasks: Resting face, emotional expressions, spontaneous speech

Audio Recording Session

Speech assessment includes:

Sustained vowel: /a/ for 5 seconds

Diadochokinetic: /pa-ta-ka/ repeated rapidly

Reading passage: Standardized text

Free conversation: 2-3 minutes spontaneous speech

Voice handicap index: Patient-reported outcomes

Technology Platform

Mobile Application Features

The data collection app provides:

User-friendly interface: Easy patient interaction
Quality control: Automated detection of suboptimal recordings
Secure data transmission: HIPAA-compliant cloud storage
Offline capability: Local data storage with sync

Data Processing Architecture

Edge computing: On-device preprocessing
Cloud-based ML: Server-side model inference
Federated learning: Privacy-preserving model improvement
Real-time feedback: Immediate results for clinicians

Clinical Significance

Diagnostic Applications

Digital facial and speech biomarkers can:

Aid early diagnosis: Detect subtle changes before clinical presentation

Support differential diagnosis: Distinguish PD from PSP, MSA, CBS

Screen at-risk individuals: Family members, prodromal subjects

Reduce diagnostic latency: Faster specialist referral

Remote Monitoring

The digital approach enables:

Telehealth assessment: Remote clinical evaluation
Continuous monitoring: Beyond episodic clinic visits
Home-based trials: Virtual clinical trial capabilities
Global accessibility: Reaching underserved populations

Therapeutic Development

Digital biomarkers support:

Clinical trial endpoints: Sensitive, objective outcome measures
Personalized treatment: Phenotype-driven therapy selection
Drug development: Enrichment strategies for targeted therapies
Device development: Optimizing speech/face therapy devices

Regulatory Considerations

FDA Perspective on Digital Endpoints

The FDA has expressed interest in digital biomarkers:

Letter of Support: For digital endpoints in neurological trials
Biomarker qualification: Pathway for digital biomarker validation
Real-world evidence: Integration of digital data in regulatory decisions

Validation Requirements

Digital biomarkers must demonstrate:

Analytical validity: Technical performance characteristics

Clinical validity: Correlation with clinical outcomes

Clinical utility: Impact on patient care

Regulatory compliance: Medical device classification

Patient Perspectives and Engagement

User Experience Considerations

The successful implementation of AI-based digital biomarkers depends heavily on patient acceptance and engagement. Several factors influence adoption:

Accessibility: The system must work across diverse populations, accounting for variations in:

Skin tone and facial structure diversity
Accent and dialect in speech analysis
Technology literacy levels
Physical limitations affecting speech or facial movement

Privacy Concerns: Patients may have reservations about video and audio recording. The study addresses this through:

Clear informed consent processes
Data anonymization protocols
Secure storage and transmission
Transparent usage policies

Engagement Strategies: Maintaining patient engagement over time requires:

User-friendly interfaces
Regular feedback on progress
Integration with clinical care
Clear communication of results

Clinical Workflow Integration

The digital biomarker system must integrate seamlessly into clinical workflows:

Data Collection: Standardized protocols ensure consistent data quality:

Defined recording environments
Calibrated equipment
Training for healthcare providers
Quality assurance checks

Result Interpretation: Clinicians receive:

Automated analysis reports
Comparison to previous assessments
Flagging of significant changes
Integration with electronic health records

Technical Challenges and Solutions

Handling Data Variability

Speech and facial data exhibit significant variability that AI systems must handle:

Environmental Factors:

Background noise in audio recordings
Variable lighting conditions for video
Recording device quality differences
Network latency in remote collection

Biological Variability:

Natural facial asymmetry
Day-to-day fluctuations in symptoms
Medication state effects
Fatigue and time-of-day variations

Solution Approaches:

Multi-sample averaging
Normalization algorithms
Quality control flags
Machine learning robustness training

Algorithm Transparency and Explainability

Clinical adoption requires understanding how AI systems reach their conclusions:

Feature Attribution: Identifying which specific facial or speech features drive predictions:

Importance weighting for different features
Visual heatmaps for facial analysis
Audio spectrogram highlighting
Correlation with clinical measures

Confidence Metrics: Providing uncertainty estimates:

Bounded confidence intervals
Out-of-distribution detection
Failure mode identification
Calibration with clinical outcomes

Health Equity Considerations

Addressing Disparities

Digital biomarkers must be developed and validated across diverse populations:

Demographic Diversity:

Age-related changes in facial structure and speech
Sex differences in baseline characteristics
Racial and ethnic representation
Geographic and socioeconomic variation

Disease Subtype Considerations:

Atypical parkinsonian disorders
Young-onset versus late-onset PD
Medication-induced versus idiopathic features
Motor fluctuations and dyskinesias

Accessibility Features

The technology should be accessible to patients with varying abilities:

Visual Impairments: Audio-based alternatives and screen reader compatibility

Motor Impairments: Alternative input methods and extended response times

Cognitive Impairments: Simplified interfaces and caregiver-assisted data collection

Health Economic Implications

Cost-Effectiveness Analysis

Digital biomarkers may provide economic benefits:

Reduced Assessment Costs: Compared to in-person specialist visits:

Lower infrastructure requirements
Remote data collection capabilities
Automated analysis reducing clinician time

Improved Resource Allocation:

Triage function for specialist referral
Monitoring between clinic visits
Early intervention identification

Reimbursement Considerations

Coverage and reimbursement pathways for digital biomarkers:

Current Landscape: Limited precedent for digital biomarker reimbursement

Potential Pathways:

CMS coverage for remote monitoring
Private payer coverage for digital health
Value-based care arrangements
Clinical trial endpoint qualification

Future Directions and Emerging Technologies

Multimodal Integration

Future systems will likely integrate multiple data streams:

Combined Analysis:

Facial and speech integration with gait analysis
Integration with wearable sensor data
Correlation with digital motor assessments
Home environment monitoring

Personalized Baselines:

Individual baseline establishment
Deviation detection algorithms
Personalized change thresholds

Advanced AI Architectures

Emerging AI approaches may improve accuracy:

Foundation Models: Large pre-trained models for transfer learning:

Reduced data requirements
Better generalization across populations
Continuous improvement capabilities

Federated Learning: Privacy-preserving model training:

Multiple institutions contributing data
Shared model improvements
Data remains localized

Conclusion

The AI-Based Facial/Speech Patterns study (NCT07392411) represents a significant step forward in the development of objective, quantifiable biomarkers for Parkinson's disease and related neurodegenerative disorders. By leveraging advances in computer vision and speech signal processing, this study may establish a new paradigm for disease monitoring that complements traditional clinical assessments.

The integration of artificial intelligence with clinical neurology offers the potential to transform patient care through more frequent and objective monitoring, earlier detection of changes, and more responsive treatment adjustments. While challenges remain in validation, regulatory approval, and clinical implementation, the trajectory of this field suggests that AI-powered digital biomarkers will become an important component of neurological care in the coming decade.

Additional Resources

For Patients

Parkinson's Foundation resources on digital health
Support groups for individuals with movement disorders
Educational materials on speech and facial therapy

For Clinicians

Training modules on digital biomarker interpretation
Integration guidelines for electronic health records
Quality assurance protocols for data collection

For Researchers

Open-source facial analysis toolkits
Speech analysis software packages
Collaborative research networks

Page updated: 2026-03-28

References

[ClinicalTrials.gov NCT07392411](https://clinicaltrials.gov/study/NCT07392411)[@aibased]

[Arora et al., Detecting Parkinson's disease from speech (2018)](https://pubmed.ncbi.nlm.nih.gov/29661667/)[@Arora_2018]

[Rusz et al., Quantitative speech analysis in parkinsonian disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33880876/)[@Rusz_2021]

[Ma et al., Automated facial expression analysis in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32295619/)[@Ma_2020]

[Tsanas et al., Acoustic analysis of speech in PD (2012)](https://pubmed.ncbi.nlm.nih.gov/22816453/)[@Tsanas_2012]

[Hanczar et al., Machine learning for PD detection (2023)](https://pubmed.ncbi.nlm.nih.gov/37451732/)[@Hanczar_2023]

[Oung et al., Digital biomarkers for PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35643792/)[@Oung_2022]

[Scarpetta et al., Facial masking in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37093102/)[@Scarpetta_2023]

[Logi et al., Voice analysis in neurodegenerative disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35147123/)[@Logi_2022]

[Perez-Llorens et al., AI-based digital phenotyping (2023)](https://pubmed.ncbi.nlm.nih.gov/37654278/)[@Perez_Llorens_2023]

[De Angelis et al., Computer vision in PD assessment (2022)](https://pubmed.ncbi.nlm.nih.gov/35680971/)[@De_Angelis_2022]

[Marsal-Catala et al., Remote monitoring via speech (2024)](https://pubmed.ncbi.nlm.nih.gov/38331056/)[@Marsal_Catala_2024]

[催 et al., Digital speech biomarkers (2022)](https://pubmed.ncbi.nlm.nih.gov/35287234/)[@催_2022]

[Moreau et al., Emotional facial expressions in PD (2008)](https://pubmed.ncbi.nlm.nih.gov/18682329/)[@Moreau_2008]

[Bologna et al., Motor and non-motor speech impairment in PD (2016)](https://pubmed.ncbi.nlm.nih.gov/26895683/)[@Bologna_2016]

Page updated: 2026-03-27

📖 View canonical wiki page →

Related Entities

clinical-trials-ai-facial-speech-patterns-pd-nct07392411

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-ai-facial-speech-patterns-pd-nct07392411
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6e76d277aaff
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-ai-facial-speech-patterns-pd-nct07392411'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

6

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ai-facial-speech-patterns-pd-nct07392411

AI-Based Facial/Speech Patterns in Parkinson's Disease (NCT07392411)

Overview

AI-Based Facial/Speech Patterns in Parkinson's Disease (NCT07392411)

Overview

Study Details

Scientific Background

Facial Expression Impairment in Parkinson's Disease

Speech Impairment in Parkinson's Disease

Objectives

Primary Objectives

Secondary Objectives

Technology and Methods

Computer Vision Pipeline

Speech Processing

Machine Learning Classifiers

Clinical Assessments

Motor Evaluation

Facial Expression Rating

Speech Assessment

Patient-Reported Outcomes

Target Populations

Parkinson's Disease

Progressive Supranuclear Palsy

Significance and Applications

Clinical Utility

Research Applications

Healthcare Delivery

Digital Biomarkers in Neurodegeneration

Comparison of Digital Measures

Emerging Evidence

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

See Also

External Links

Related Pages

Facial Dysfunction: Hypomimia and Masking

Pathophysiology

Clinical Manifestations

Speech Dysfunction: Hypokinetic Dysarthria

Speech Characteristics

Neuroanatomical Basis

Facial-Speech Connection in PSP

AI-Powered Digital Biomarkers

Computer Vision for Facial Analysis

Technical Approach

Machine Learning Pipeline

Clinical Applications

Speech Signal Processing

Acoustic Feature Extraction

Machine Learning Classification

Digital Biomarker Validation

Cross-Modal Validation

Correlation with Clinical Measures

Clinical Trial Design

Study Population

Target Conditions

Sample Size Considerations

Assessment Protocol

Video Recording Session

Audio Recording Session

Technology Platform

Mobile Application Features

Data Processing Architecture

Clinical Significance

Diagnostic Applications

Remote Monitoring

Therapeutic Development

Regulatory Considerations

FDA Perspective on Digital Endpoints

Validation Requirements

Patient Perspectives and Engagement

User Experience Considerations

Clinical Workflow Integration

Technical Challenges and Solutions

Handling Data Variability

Algorithm Transparency and Explainability

Health Equity Considerations